Search Results

Overview

Uniprot IDP17516
Protein NameAldo-keto reductase family 1 member C4
Gene NameAKR1C4
OrganismHomo sapiens

Kla Sites from experimental identification

Position Flanking peptide
161 CKDAGLAKSIGVSNF
183 ILNKPGLKYKPVCNQ
185 NKPGLKYKPVCNQVE
207 SKLLDFCKSKDIVLV
209 LLDFCKSKDIVLVAH
225 ALGTQRHKLWVDPNS
246 PVLCALAKKHKQTPA
39 NRAVEVTKLAIEAGF
4 ****MDPKYQRVELN

Function

Cytosolic aldo-keto reductase that catalyzes NADPH-dependent reduction of ketosteroids to hydroxysteroids. Displays broad substrate specificity with distinct positional and stereochemistry, primarily generating 3alpha/beta-, 17beta- and 20alpha-hydroxysteroids (PubMed:10634139, PubMed:10998348, PubMed:11158055, PubMed:14672942, PubMed:1530633, PubMed:12604236, PubMed:19218247, PubMed:21802064, PubMed:7650035). Required for male sex determination as a component of the 'backdoor' androgen biosynthesis pathway that generates 5alpha-dihydrotestosterone (5alpha-DHT) via pregnanes. Acts together with AKR1C2 to convert 5alpha-dihydroprogesterone (5alpha-DHP) to 3alpha-hydroxy-5alpha-pregnan-20-one (3alpha,5alpha-THP/allopregnanolone), leading to 5alpha-DHT secretion necessary for embryonic gonad differentiation into testis (PubMed:21802064). May regulate the concentrations of circulating neurosteroids. Reduces 5alpha-dihydroprogesterone (5-alpha-DHP) and 5alpha-dihydrodeoxycorticosterone (5-alpha-DHDOC) precursors to 3alpha-hydroxy-5alpha-pregnan-20-one (3alpha,5alpha-THP/allopregnanolone) and 3alpha,21-dihydroxy-5alpha-pregnane-20-one (3alpha,5alpha-THDOC) neuroactive steroids known to alter neural excitability via allosteric activation of gamma-aminobutyric acid type A receptors (GABAAR) (PubMed:12604236). Regulates ligand availability for steroid hormone receptors. Catalyzes the inactivation of 5alpha-DHT and progesterone converting them into 3alpha/beta-androstanediols and (20S)-hydroxypregn-4-en-3-one, respectively (PubMed:10998348, PubMed:11158055, PubMed:14672942). May contribute to the metabolism of adrenal-derived androgens via reduction of 11-keto-5alpha-androstane-3,17-dione (11K-Adione) into 11-ketoandrosterone (11KAST) and of 11-ketodihydrotestosterone (11KDHT) into 11-keto-5alpha-androstane-3alpha/beta,17beta-diol (11K-A3diol) (PubMed:31926269). Catalyzes the reduction of estrone into 17beta-estradiol but with low efficiency (PubMed:14672942). In androgen catabolism, may predominantly act as a phase I enzyme by introducing a hydroxyl group prior to conjugation. It can nevertheless participate in the alternative phase II pathway by directly reducing sulfate- or glucuronide-conjugated androgens (PubMed:19218247). Catalyzes the biotransformation of the pesticide chlordecone (kepone) to its corresponding alcohol, leading to increased biliary excretion of the pesticide and concomitant reduction of its neurotoxicity since bile is the major excretory route (PubMed:2427522). In vitro can efficiently catalyze bidirectional conversion between ketosteroids and hydroxysteroids using NADPH/NADP(+) or NADH/NAD(+) as cofactors. In vivo however, the reductase activity prevails since the major reducing cofactor NADPH inhibits NAD(+)-dependent oxidase activity (PubMed:14672942)

Protein Sequence

10 MDPKYQRVEL 20 NDGHFMPVLG 30 FGTYAPPEVP 40 RNRAVEVTKL 50 AIEAGFRHID 60 SAYLYNNEEQ 70 VGLAIRSKIA 80 DGSVKREDIF 90 YTSKLWCTFF 100 QPQMVQPALE 110 SSLKKLQLDY 120 VDLYLLHFPM 130 ALKPGETPLP 140 KDENGKVIFD 150 TVDLSATWEV 160 MEKCKDAGLA 170 KSIGVSNFNC 180 RQLEMILNKP 190 GLKYKPVCNQ 200 VECHPYLNQS 210 KLLDFCKSKD 220 IVLVAHSALG 230 TQRHKLWVDP 240 NSPVLLEDPV 250 LCALAKKHKQ 260 TPALIALRYQ 270 LQRGVVVLAK 280 SYNEQRIREN 290 IQVFEFQLTS 300 EDMKVLDGLN 310 RNYRYVVMDF 320 LMDHPDYPFS DEY

Gene Ontology

Classification GO ID Description
Biological Process GO:0015721 bile acid and bile salt transport
Cellular Component GO:0005737 cytoplasm
Cellular Component GO:0005829 cytosol
Cellular Component GO:0070062 extracellular exosome
Molecular Function GO:0140169 3-alpha-hydroxysteroid 3-dehydrogenase [NAD(P)+] activity
Molecular Function GO:0047024 5-alpha-androstane-3-beta,17-beta-diol dehydrogenase (NADP+) activity
Molecular Function GO:0008106 alcohol dehydrogenase (NADP+) activity
Molecular Function GO:0004032 aldose reductase (NADPH) activity
Molecular Function GO:0047044 androstan-3-alpha,17-beta-diol dehydrogenase (NAD+) activity
Molecular Function GO:0047023 androsterone dehydrogenase [NAD(P)+] activity
Molecular Function GO:0032052 bile acid binding
Molecular Function GO:0015125 bile acid transmembrane transporter activity
Molecular Function GO:0047743 chlordecone reductase activity
Molecular Function GO:0009055 electron transfer activity
Molecular Function GO:0004303 estradiol 17-beta-dehydrogenase [NAD(P)+] activity
Molecular Function GO:0047086 ketosteroid monooxygenase activity
Molecular Function GO:0016655 oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor
Molecular Function GO:0001758 retinal dehydrogenase (NAD+) activity
Molecular Function GO:0047035 testosterone dehydrogenase (NAD+) activity
Molecular Function GO:0047045 testosterone dehydrogenase (NADP+) activity
Biological Process GO:0008209 androgen metabolic process
Biological Process GO:0006699 bile acid biosynthetic process
Biological Process GO:0071395 cellular response to jasmonic acid stimulus
Biological Process GO:0044597 daunorubicin metabolic process
Biological Process GO:0044598 doxorubicin metabolic process
Biological Process GO:0042448 progesterone metabolic process
Biological Process GO:0006693 prostaglandin metabolic process
Biological Process GO:0001523 retinoid metabolic process
Biological Process GO:0008202 steroid metabolic process

Reference

[1] Yang Z, Yan C, Ma J, Peng P, Ren X et al.. Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma.. Nat Metab 5(1):61-79. 2023 Jan. PMID: 36593272.

[2] Hong H, Chen X, Wang H, Gu X, Yuan Y et al.. Global profiling of protein lysine lactylation and potential target modified protein analysis in hepatocellular carcinoma.. Proteomics 23(9):e2200432. 2023 May. PMID: 36625413.